Nebivolol Teva

Nebivolol, the active ingredient in Nebivolol Teva, is a beta blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and heart failure in adult patients, helping to lower blood pressure and improve cardiac performance.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management. - Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: especially upon standing. - Fatigue: general tiredness. - Nasal congestion: mild blockage. - Diarrhea: loose stools. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe bradycardia: may require medical attention. - Heart block: conduction abnormalities. - Acute heart failure worsening: rare but serious. - Hypotension: marked drop in blood pressure. - Bronchospasm: especially in patients with asthma. - Allergic reactions: rash, itching, or swelling.

Before prescribing Nebivolol, clinicians should assess patient history and comorbidities. - Cardiovascular disease: evaluate for bradycardia or heart block. - Asthma or COPD: monitor for bronchospasm. - Diabetes: watch for masking of hypoglycemia symptoms. - Liver impairment: consider dose adjustment. - Pregnancy and lactation: use only if clearly needed; safety data are limited. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Other β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): heightened risk of heart block.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may mask hypoglycemia signs. - NSAIDs: can reduce antihypertensive effect. - Diuretics: may potentiate hypotensive response.